These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23557017)

  • 61. The interaction between intellectual property and drug regulatory systems: global perspectives.
    Madden EA
    IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 2012 in review - part II: overcoming the obstacles in the pharma/biotech industry.
    Rabasseda X; Dulsat C; Navarro D; Cruces E; Graul AI; Jago C; Tracy M
    Drugs Today (Barc); 2013 Feb; 49(2):117-43. PubMed ID: 23462626
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [PHARMACEUTICAL INDUSTRY AND PERSONALIZED MEDICINE: A PARADIGM SHIFT IN THE DEVELOPMENT OF NEW DRUGS].
    Scheen AJ
    Rev Med Liege; 2015; 70(5-6):237-41. PubMed ID: 26285445
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Drug discovery alliances in India--indications, targets, and new chemical entities.
    Differding E
    ChemMedChem; 2014 Jan; 9(1):43-60. PubMed ID: 24136820
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The development of Bio-pharmaceutical industry in China: problems and solutions.
    Yan G
    Pak J Pharm Sci; 2014 Jul; 27(4 Suppl):1035-9. PubMed ID: 25016263
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Discovery and development of new antibacterial drugs: learning from experience?
    Jackson N; Czaplewski L; Piddock LJV
    J Antimicrob Chemother; 2018 Jun; 73(6):1452-1459. PubMed ID: 29438542
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Innovative antibacterial drugs: nothing ventured, nothing gained.
    Stein J
    Expert Opin Investig Drugs; 2005 Feb; 14(2):107-9. PubMed ID: 15757389
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharma's developing interest in stem cells.
    McKernan R; McNeish J; Smith D
    Cell Stem Cell; 2010 Jun; 6(6):517-20. PubMed ID: 20569688
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Orphan drug: Development trends and strategies.
    Sharma A; Jacob A; Tandon M; Kumar D
    J Pharm Bioallied Sci; 2010 Oct; 2(4):290-9. PubMed ID: 21180460
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU.
    Annemans L; Cleemput I; Hulstaert F; Simoens S
    J Comp Eff Res; 2012 Jan; 1(1):19-29. PubMed ID: 24237295
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The changing model of big pharma: impact of key trends.
    Gautam A; Pan X
    Drug Discov Today; 2016 Mar; 21(3):379-84. PubMed ID: 26477304
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Drug discovery and development tomorrow -- changing the mindset.
    Coleman RA
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():1-4. PubMed ID: 19807197
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Big Pharma's small wonder.
    Fry E
    Fortune; 2014 Jun; 169(8):178-84, 186. PubMed ID: 25211849
    [No Abstract]   [Full Text] [Related]  

  • 74. Big Pharma: a former insider's view.
    Badcott D
    Med Health Care Philos; 2013 May; 16(2):249-64. PubMed ID: 22351152
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry.
    Dierks RM; Bruyère O; Reginster JY; Richy FF
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):571-578. PubMed ID: 27653356
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.
    Halim AB
    Ann N Y Acad Sci; 2015 Jun; 1346(1):63-70. PubMed ID: 25758153
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.
    O'Brien S
    Br J Clin Pharmacol; 2015 Feb; 79(2):168-72. PubMed ID: 25601037
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
    Povsic TJ; Scott R; Mahaffey KW; Blaustein R; Edelberg JM; Lefkowitz MP; Solomon SD; Fox JC; Healy KE; Khakoo AY; Losordo DW; Malik FI; Monia BP; Montgomery RL; Riesmeyer J; Schwartz GG; Zelenkofske SL; Wu JC; Wasserman SM; Roe MT
    Cardiovasc Drugs Ther; 2017 Aug; 31(4):445-458. PubMed ID: 28735360
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals.
    Bettiol E; Wetherington JD; Schmitt N; Harbarth S;
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3695-9. PubMed ID: 25918147
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New Zealand's drug development industry.
    Lockhart MM; Babar ZU; Carswell C; Garg S
    Int J Environ Res Public Health; 2013 Sep; 10(9):4339-51. PubMed ID: 24065037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.